8 completed, 7 recruiting, 4 not yet recruiting, 1 active not recruiting. 15 Phase 1, 11 Phase 2, 4 Phase 3.
Follow Evopoint Biosciences Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer XNW28012 - Metastatic Pancreatic Cancer | Phase 1 | Not yet recruiting | Evopoint Biosciences Inc. | 24 | 2026-07-30 | 2026-07-22 |
| Study of XNW5004 Tablets in Advanced Prostate Cancer XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 242 | 2026-07-13 | 2026-07-28 |
| Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma XNW5004 tablets - Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2 | Phase 2 | Recruiting | Evopoint Biosciences Inc. | 65 | 2026-02-14 | 2026-04-22 |
| A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor XNW34017 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 150 | 2026-01-31 | 2026-01-08 |
| Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended) - Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 176 | 2025-08-15 | 2026-07-29 |
| Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy XNW28012 for injection, XNW28012 Mimetic for Injection - Pancreatic Cancer | Phase 3 | Recruiting | Evopoint Biosciences Inc. | 226 | 2025-07-08 | 2026-09-16 |
| A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment XNW29016 - Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 132 | 2025-04-11 | 2026-10-16 |
| A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma XNW5004 ; Chidamide placebo, XNW5004 placebo; Chidamide - Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 3 | Recruiting | Evopoint Biosciences Inc. | 120 | 2025-04-10 | 2026-01-09 |
| To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma XNW5004 tablets - Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 50 | 2024-11-01 | 2024-11-25 |
| Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments XNW28012 - Advanced Solid Tumors, Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 350 | 2023-12-01 | 2026-04-15 |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Terminated | Evopoint Biosciences Inc. | 12 | 2023-09-20 | 2026-07-23 |
| XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. XNW27011 - Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Active not recruiting | Astellas Pharma Global Development, Inc. | 240 | 2023-07-27 | 2026-08-11 |
| Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer XNW5004, enzalutamide - Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 307 | 2023-04-19 | 2026-10-20 |
| Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40) Combination of Imipenem/Cilastatin and XNW4107, Meropenem - Complicated Urinary Tract Infection Including Acute Pyelonephritis | Phase 3 | Unknown | Evopoint Biosciences Inc. | 780 | 2023-03-30 | 2023-02-16 |
| Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam - Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia | Phase 3 | Completed | Evopoint Biosciences Inc. | 450 | 2022-07-31 | 2025-11-06 |
| To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors XNW5004 tablets - Advanced Tumor, Lymphoma | Phase 1 / Phase 2 | Completed | Evopoint Biosciences Inc. | 120 | 2021-08-03 | 2026-10-20 |
| Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects XNW4107, Imipenem/Cilastatin - Bacterial Infections | Phase 1 | Completed | Evopoint Biosciences Inc. | 21 | 2021-03-25 | 2023-02-16 |
| To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females. XNW4107, Imipenem/Cilastatin, placebo - Bacterial Infections | Phase 1 | Completed | Evopoint Biosciences Inc. | 24 | 2021-03-02 | 2023-02-16 |
| Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function XNW4107, Imipenem/Cilastatin - Bacterial Infections | Phase 1 | Completed | Evopoint Biosciences Inc. | 39 | 2021-02-25 | 2023-02-16 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin XNW4107 - Bacterial Infections | Phase 1 | Completed | Evopoint Biosciences Inc. | 88 | 2020-07-10 | 2023-02-16 |
Showing 20 of 22. Sign in to see all of them.
Bacterial Infections (4) · Lymphoma, T-Cell, Peripheral (3) · Pancreatic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Ovarian Neoplasms (2) · Uterine Cervical Neoplasms (2) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Carcinoma, Transitional Cell (1) · Gout (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1)
Cilastatin (4) · Imipenem (2) · Injections (2) · Prednisone (2) · enzalutamide (2) · BID protein, human (1) · Cilastatin, Imipenem Drug Combination (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Etoposide (1) · Lead (1) · Meropenem (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · Postprandial Period (1)
China (11) · United States (7) · Australia (2) · France (1) · Israel (1) · Spain (1)
Jason Le (5) · D Ye, M.D. (1) · Li Zhang, M.D. (1) · QI Junyuan (1) · Qiu Lugui (1) · Sam Salman (1) · Yuqin Song, PhD (1)